Staphefekt Explained

Staphefekt is a proprietary enzyme (an endolysin) intended to treat Staphylococcus aureus skin infections in humans. It is developed and produced by the Dutch biotechnology company Micreos.[1] [2] It became the first commercially available endolysin and is marketed in Gladskin products.[3]

The enzyme has been shown to be effective in killing S. aureus strains resistant to antibiotics such as MRSA.[4] The enzyme has successfully been used for treatment of S. aureus-related dermatosis.[5]

Notes and References

  1. Parmley. Stephen . vanc . 2014-12-11. Lysin in wait. SciBX: Science-Business EXchange. en. 7. 47. 1369. 10.1038/scibx.2014.1369.
  2. Herpers BL, Leeson N . Endolysins: redefining antibacterial therapy . Future Microbiology . 10 . 3 . 309–11 . 2015-03-01 . 25812452 . 10.2217/fmb.14.142 . 45404710 .
  3. Web site: Technology. Gladskin EU. en-eu. 2020-01-10.
  4. News: Endolysin Technology Presents an Antibiotic Alternative with Broad Applicability. Siew. Adeline. vanc . Apr 21, 2015. www.pharmtech.com.
  5. Totté JE, van Doorn MB, Pasmans SG . Staphylococcus aureus-Related Dermatoses with the Topical Endolysin Staphefekt SA.100: A Report of 3 Cases . Case Reports in Dermatology . 9 . 2 . 19–25 . 2017-05-22 . 28611631 . 5465516 . 10.1159/000473872 .

This article is licensed under the GNU Free Documentation License. It uses material from the Wikipedia article "Staphefekt".

Except where otherwise indicated, Everything.Explained.Today is © Copyright 2009-2024, A B Cryer, All Rights Reserved. Cookie policy.